Insider Transactions in Q3 2025 at Karyopharm Therapeutics Inc. (KPTI)
Insider Transaction List (Q3 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 15
2025
|
Richard A. Paulson President and CEO |
SELL
Open market or private sale
|
Direct |
1,257
-1.47%
|
$7,542
$6.43 P/Share
|
|
Sep 15
2025
|
Kristin Abate Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
23
-0.22%
|
$138
$6.43 P/Share
|
|
Sep 15
2025
|
Sohanya Roshan Cheng EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
325
-0.9%
|
$1,950
$6.43 P/Share
|
|
Sep 15
2025
|
Reshma Rangwala EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
408
-1.37%
|
$2,448
$6.43 P/Share
|
|
Sep 15
2025
|
Stuart Poulton EVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
401
-1.43%
|
$2,406
$6.43 P/Share
|
|
Sep 15
2025
|
Michael Mano SVP, General Counsel&Secretary |
SELL
Open market or private sale
|
Direct |
234
-1.08%
|
$1,404
$6.43 P/Share
|
|
Sep 12
2025
|
Richard A. Paulson President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
2,800
+3.18%
|
-
|
|
Sep 12
2025
|
Kristin Abate Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46
+0.44%
|
-
|
|
Sep 12
2025
|
Sohanya Roshan Cheng EVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
945
+2.55%
|
-
|
|
Sep 12
2025
|
Reshma Rangwala EVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
945
+3.07%
|
-
|
|
Sep 12
2025
|
Stuart Poulton EVP, Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
888
+3.06%
|
-
|
|
Sep 12
2025
|
Michael Mano SVP, General Counsel&Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
612
+2.75%
|
-
|
|
Sep 03
2025
|
Kristin Abate Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
12
-0.13%
|
$72
$6.78 P/Share
|
|
Jul 29
2025
|
Stuart Poulton EVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
191
-0.7%
|
$764
$4.37 P/Share
|
|
Jul 22
2025
|
Kristin Abate Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
238
-2.45%
|
$952
$4.0 P/Share
|